HER2 testing in gastric cancer: An update
Lucas Faria Abrahao-Machado, Cristovam Scapulatempo-Neto, Lucas Faria Abrahao-Machado, Cristovam Scapulatempo-Neto
Abstract
Human epidermal growth factor receptor 2 (HER2) overexpression is increasingly recognized as a frequent molecular abnormality in gastric and gastroesophageal cancer. With the recent introduction of HER2 molecular targeted therapy for patients with advanced gastric cancer, determination of HER2 status is crucial in order to select patients who may benefit from this treatment. This paper provides an update on our knowledge of HER2 in gastric and gastroesophageal cancer, including the prognostic relevance of HER2, the key differences between HER2 protein expression interpretation in breast and gastric cancer, the detection methods and the immunohistochemistry scoring system.
Keywords: Gastric cancer; Human epidermal growth factor receptor 2 testing; Immunohistochemistry; Scoring system; Trastuzumab.
Figures
Source: PubMed